Molecular analysis of the maternal-fetal interface in preeclampsia
Official title: Molecular Study of the Maternal-fetal Interface Prospectively to the Onset of Preeclampsia Using Single Cell Technology.
Run by Carlos Simon Foundation · NCT06232668 · Data updated 2026-11-12
This study is trying to find specific markers in early pregnancy that could help identify women at risk for preeclampsia, using samples from those undergoing routine testing.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 2084 (estimated) |
| Sponsor | Carlos Simon Foundation Academic / other |
| Locations | 4 sites (Alicante, Alicante and 3 other locations) |
| Status | Recruiting |
| Started | November 20, 2023 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT06232668 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are pregnant women over the age of 18 who are between 9 and 14 weeks of gestation and are undergoing chorionic villus biopsy due to a risk of fetal chromosomal abnormalities.
✕Probably not a fit
Patients with multiple pregnancies or non-evolving pregnancies will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify molecular markers and aberrant cell types at the maternal-fetal interface during early pregnancy in women at risk for preeclampsia. By collecting chorionic villi samples from pregnant women undergoing aneuploidy testing between 9 and 14 weeks of gestation, the study will utilize single-cell sequencing technology to analyze the molecular profiles associated with preeclampsia. The goal is to characterize the early development of preeclampsia and improve early detection and prevention strategies.
Why it matters
Potential benefit: If successful, this study could lead to early identification and intervention for women at risk of developing preeclampsia, potentially reducing maternal and fetal morbidity and mortality.
How similar studies have gone: While the approach of using single-cell sequencing for early detection of preeclampsia is innovative, similar studies have shown promise in identifying biomarkers for other obstetric complications.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved. * Women over the age of 18 at the time of signing the informed consent form. * Women who meet at least one of the following criteria at the time of inclusion: Phase 1 (first trimester): Pregnant women between 9 and 15 weeks of gestation who are scheduled to undergo chorionic villus sampling (CVS) as part of the center's routine clinical practice. Phase 2 (delivery): Women with an ongoing pregnancy, regardless of gestational age and without the requirement of having participated in Phase 1, who are willing to donate placental and maternal blood samples following delivery. Exclusion Criteria: * Women with multiple pregnancy. * Non-evolving pregnancies (including delayed abortion/foetal orbit).
Where it's running
-
Hospital General Universitario Dr. Balmis
Alicante, Alicante, Spain Recruiting -
Hospital Clinico Universitario Virgen de la Arrixaca
Murcia, Murcia, Spain Recruiting -
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain Recruiting -
Hospital Universitario y Politécnico La Fe
Valencia, Valencia, Spain Recruiting
Study contacts
- Principal investigator: Tamara Garrido, PhD — Fundación Carlos Simon para la investigación en salud de la mujer
- Study coordinator: Érika Ortiz, BSc, MSc
- Email: clinicalstudies@fundacioncarlossimon.com
- Phone: +34962938210
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy
This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.
-
Higher vs lower daily aspirin in high-risk pregnant people
This study tests whether taking 150 mg of aspirin daily is more effective than 75 mg daily in preventing preeclampsia among pregnant people at high risk.
-
Community health worker support to lower blood pressure after pregnancy with high blood pressure
Postpartum patients with high blood pressure after pregnancy will try a program where a trained community health worker helps them monitor blood pressure and manage care for 6 months to see if it lowers blood pressure compared with usual care.
-
Role of Progesterone Membrane Receptors in Preeclampsia
This study looks at whether the levels of progesterone membrane receptors in the placenta differ between women with preeclampsia and healthy pregnant women to understand the condition better.
-
Endothelial Biomarkers in Pregnancy: Endothelial Extracellular Vesicles and Hypertensive Disorders
This study tests whether endothelial extracellular vesicles in the blood differ between normotensive pregnant women and those with hypertensive disorders of pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.